Harrow Inc
HROW34.930USD
+3.560+11.35%
Cierre 07/11, 16:00（ET）Cotizaciones retrasadas 15 min
1.25BCap. mercado
PérdidaP/E TTM
Más Datos de Harrow Inc Compañía
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Información de la empresa
Símbolo de cotizaciónHROW
Nombre de la empresaHarrow Inc
Fecha de salida a bolsaFeb 08, 2013
Fundada en2006
Director ejecutivoMr. John P. Saharek
Número de empleados382
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 08
Dirección1A Burton Hills Blvd
CiudadNASHVILLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal37215
Teléfono16157334731
Sitio Webhttps://www.harrow.com/
Símbolo de cotizaciónHROW
Fecha de salida a bolsaFeb 08, 2013
Fundada en2006
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.60M
+21.61%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.60M
+21.61%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Desglose de ingresos
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Opaleye Management Inc.
10.72%
Baum (Mark L)
7.08%
BlackRock Institutional Trust Company, N.A.
6.20%
Private Capital Management
5.15%
The Vanguard Group, Inc.
5.07%
Other
65.78%
Accionistas
Accionistas
Proporción
Opaleye Management Inc.
10.72%
Baum (Mark L)
7.08%
BlackRock Institutional Trust Company, N.A.
6.20%
Private Capital Management
5.15%
The Vanguard Group, Inc.
5.07%
Other
65.78%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
23.15%
Hedge Fund
18.11%
Individual Investor
15.07%
Investment Advisor
12.93%
Research Firm
2.04%
Pension Fund
0.45%
Bank and Trust
0.33%
Sovereign Wealth Fund
0.07%
Insurance Company
0.03%
Other
27.83%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
340
26.58M
72.44%
-3.00M
2025Q1
354
25.78M
70.87%
-4.22M
2024Q4
350
26.13M
73.38%
-4.49M
2024Q3
325
25.90M
72.95%
-2.80M
2024Q2
296
24.70M
70.19%
-6.36M
2024Q1
284
26.34M
74.95%
-7.20M
2023Q4
279
28.26M
80.94%
-4.94M
2023Q3
275
28.51M
81.73%
-152.59K
2023Q2
265
25.64M
85.30%
+312.85K
2023Q1
246
23.86M
79.81%
+1.57M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Opaleye Management Inc.
3.94M
10.72%
-4.80K
-0.12%
Jun 04, 2025
Baum (Mark L)
2.60M
7.08%
+461.94K
+21.61%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
2.27M
6.2%
-1.07K
-0.05%
Mar 31, 2025
Private Capital Management
1.89M
5.15%
+195.64K
+11.54%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
5.07%
-6.65K
-0.36%
Mar 31, 2025
Kaufman (Daniel)
1.68M
4.59%
-222.91K
-11.69%
Aug 12, 2024
Braidwell LP
956.84K
2.61%
+49.80K
+5.49%
Mar 31, 2025
State Street Global Advisors (US)
786.48K
2.14%
-41.22K
-4.98%
Mar 31, 2025
Boll (Andrew R)
777.84K
2.12%
+209.75K
+36.92%
Apr 21, 2025
Geode Capital Management, L.L.C.
774.08K
2.11%
+52.97K
+7.35%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
SPDR S&P Pharmaceuticals ETF
1.96%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.76%
iShares U.S. Pharmaceuticals ETF
0.48%
First Trust Small Cap Growth AlphaDEX Fund
0.4%
iShares Micro-Cap ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Fidelity Small-Mid Multifactor ETF
0.09%
First Trust Multicap Growth Alphadex Fund
0.07%
Ver más
SPDR S&P Pharmaceuticals ETF
Proporción1.96%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción0.76%
iShares U.S. Pharmaceuticals ETF
Proporción0.48%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.4%
iShares Micro-Cap ETF
Proporción0.19%
ProShares Ultra Nasdaq Biotechnology
Proporción0.13%
Invesco Nasdaq Biotechnology ETF
Proporción0.11%
Vanguard US Momentum Factor ETF
Proporción0.1%
Fidelity Small-Mid Multifactor ETF
Proporción0.09%
First Trust Multicap Growth Alphadex Fund
Proporción0.07%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
